These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Clinical, immunophenotypic, and molecular profiling of trisomy 12 in chronic lymphocytic leukemia and comparison with other karyotypic subgroups defined by cytogenetic analysis. Athanasiadou A; Stamatopoulos K; Tsompanakou A; Gaitatzi M; Kalogiannidis P; Anagnostopoulos A; Fassas A; Tsezou A Cancer Genet Cytogenet; 2006 Jul; 168(2):109-19. PubMed ID: 16843100 [TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of genetic abnormalities in 536 first-line chronic lymphocytic leukaemia patients without 17p deletion treated with chemoimmunotherapy in two prospective trials: Focus on IGHV-mutated subgroups (a FILO study). Nguyen-Khac F; Baron M; Guièze R; Feugier P; Fayault A; Raynaud S; Troussard X; Droin N; Damm F; Smagghe L; Susin S; Leblond V; Dartigeas C; Van den Neste E; Leprêtre S; Bernard OA; Roos-Weil D; Br J Haematol; 2024 Aug; 205(2):495-502. PubMed ID: 38654616 [TBL] [Abstract][Full Text] [Related]
5. Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia. Sandoval-Sus JD; Chavez JC; Dalia S; Naqvi SMH; Talati C; Nodzon L; Kharfan-Dabaja MA; Pinilla-Ibarz J Leuk Lymphoma; 2018 Jan; 59(1):59-68. PubMed ID: 28641468 [TBL] [Abstract][Full Text] [Related]
6. NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL. Del Giudice I; Rossi D; Chiaretti S; Marinelli M; Tavolaro S; Gabrielli S; Laurenti L; Marasca R; Rasi S; Fangazio M; Guarini A; Gaidano G; Foà R Haematologica; 2012 Mar; 97(3):437-41. PubMed ID: 22207691 [TBL] [Abstract][Full Text] [Related]
7. Different distribution of NOTCH1 mutations in chronic lymphocytic leukemia with isolated trisomy 12 or associated with other chromosomal alterations. López C; Delgado J; Costa D; Conde L; Ghita G; Villamor N; Navarro A; Cazorla M; Gómez C; Arias A; Muñoz C; Baumann T; Rozman M; Aymerich M; Colomer D; Cobo F; Campo E; López-Guillermo A; Montserrat E; Carrió A Genes Chromosomes Cancer; 2012 Sep; 51(9):881-9. PubMed ID: 22619094 [TBL] [Abstract][Full Text] [Related]
8. Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans. Xia Y; Fan L; Wang L; Gale RP; Wang M; Tian T; Wu W; Yu L; Chen YY; Xu W; Li JY Oncotarget; 2015 Mar; 6(7):5426-34. PubMed ID: 25605254 [TBL] [Abstract][Full Text] [Related]
9. NOTCH1 mutation and its prognostic significance in Chinese chronic lymphocytic leukemia: a retrospective study of 317 cases. Zou Y; Fan L; Xia Y; Miao Y; Wu W; Cao L; Wu J; Zhu H; Qiao C; Wang L; Xu W; Li J Cancer Med; 2018 May; 7(5):1689-1696. PubMed ID: 29573199 [TBL] [Abstract][Full Text] [Related]
10. The importance of IGHV mutational status in del(11q) and del(17p) chronic lymphocytic leukemia. Gladstone DE; Blackford A; Cho E; Swinnen L; Kasamon Y; Gocke CD; Griffin CA; Bolaños-Meade J; Jones RJ Clin Lymphoma Myeloma Leuk; 2012 Apr; 12(2):132-7. PubMed ID: 22285608 [TBL] [Abstract][Full Text] [Related]
11. Impact of trisomy 12, del(13q), del(17p), and del(11q) on the immunophenotype, DNA ploidy status, and proliferative rate of leukemic B-cells in chronic lymphocytic leukemia. Quijano S; López A; Rasillo A; Sayagués JM; Barrena S; Sánchez ML; Teodosio C; Giraldo P; Giralt M; Pérez MC; Romero M; Perdiguer L; Orfao A Cytometry B Clin Cytom; 2008 May; 74(3):139-49. PubMed ID: 18061951 [TBL] [Abstract][Full Text] [Related]
12. Distinct immunoglobulin heavy chain variable region gene repertoire and lower frequency of del(11q) in Taiwanese patients with chronic lymphocytic leukaemia. Huang YJ; Kuo MC; Chang H; Wang PN; Wu JH; Huang YM; Ma MC; Tang TC; Kuo CY; Shih LY Br J Haematol; 2019 Oct; 187(1):82-92. PubMed ID: 31230372 [TBL] [Abstract][Full Text] [Related]
13. Molecular basis of aggressive disease in chronic lymphocytic leukemia patients with 11q deletion and trisomy 12 chromosomal abnormalities. Mittal AK; Hegde GV; Aoun P; Bociek RG; Dave BJ; Joshi AD; Sanger WG; Weisenburger DD; Joshi SS Int J Mol Med; 2007 Oct; 20(4):461-9. PubMed ID: 17786276 [TBL] [Abstract][Full Text] [Related]
14. Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. Tausch E; Schneider C; Robrecht S; Zhang C; Dolnik A; Bloehdorn J; Bahlo J; Al-Sawaf O; Ritgen M; Fink AM; Eichhorst B; Kreuzer KA; Tandon M; Humphrey K; Jiang Y; Schary W; Bullinger L; Mertens D; Lurà MP; Kneba M; Döhner H; Fischer K; Hallek M; Stilgenbauer S Blood; 2020 Jun; 135(26):2402-2412. PubMed ID: 32206772 [TBL] [Abstract][Full Text] [Related]
15. Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia. Le Bris Y; Struski S; Guièze R; Rouvellat C; Prade N; Troussard X; Tournilhac O; Béné MC; Delabesse E; Ysebaert L Hematol Oncol; 2017 Dec; 35(4):664-670. PubMed ID: 27678008 [TBL] [Abstract][Full Text] [Related]